Randomised controlled trial of the tolerability and completion of Maraviroc compared to Kaletra® in combination with Truvada® for HIV Post Exposure Prophylaxis

Central and North West London NHS Foundation Trust (UK)0 个研究点目标入组 280 人开始时间: 2012年3月9日最近更新: 2018年2月26日

适应症

试验速览

•1. 18 years old or older
•2. A patient attending one of four genitourinary medicine clinics and for whom PEP is considered appropriate by the clinician according to current guidelines including following occupational or non occupational exposure
•3. Willing to provide written informed consent

•1. The baseline human immunodeficiency virus (HIV) test is reactive or positive
•2. Currently receiving medication which would reduce the effectiveness of Kaletra® / maraviroc
•3. Currently receiving medication where the interaction would result in a dangerously high level of the concomitant drug
•4. Pregnant or trying to become pregnant at the time of trial entry
•5. The source is known to have multi-drug resistant HIV and therefore more likely to have CXCR 4 tropic virus
•6. History of active substance abuse or psychiatric illness that, in the opinion of the investigator, would preclude compliance with the protocol, dosing schedule or assessments
•7. Any other active clinically significant condition, or findings during screening medical history or examination, or abnormality on screening laboratory blood tests that would, in the opinion of the investigator, compromise the patient?s safety or outcome in the trial

发起方

Central and North West London NHS Foundation Trust (UK)